Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two
Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety and tolerability
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an
Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as Editas advances
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that
EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a)
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced the
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical data supporting
EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data at upcoming
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five
